StockData
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. (TCRX) stock

TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.01 (+4.07%)

Close on Nov 17, 2026Market cap $10.23MP/E –Yield –

TScan Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2025 it was -$132.91M. The highest annual figure on record is -$25.03M in fiscal 2020.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$132.91M–
FY2024Dec 31, 2024-$130.72M–
FY2023Dec 31, 2023-$88.06M–
FY2022Dec 31, 2022-$61.54M–
FY2021Dec 31, 2021-$45.34M–
FY2020Dec 31, 2020-$25.03M–

More TScan Therapeutics figures

See a number that looks wrong?